These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 29774081)
1. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081 [No Abstract] [Full Text] [Related]
2. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872 [TBL] [Abstract][Full Text] [Related]
3. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex. Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372 [TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis. Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486 [TBL] [Abstract][Full Text] [Related]
5. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676 [TBL] [Abstract][Full Text] [Related]
6. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death. Lin YC; Sun SH; Wang FF Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628 [TBL] [Abstract][Full Text] [Related]
7. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer. Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228 [TBL] [Abstract][Full Text] [Related]
8. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171 [TBL] [Abstract][Full Text] [Related]
9. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192 [TBL] [Abstract][Full Text] [Related]
10. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers. Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184 [TBL] [Abstract][Full Text] [Related]
11. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex. Fischer M; Quaas M; Nickel A; Engeland K Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316 [TBL] [Abstract][Full Text] [Related]
14. MiRNA-875-3p alleviates the progression of colorectal cancer via negatively regulating PLK1 level. Li SS; Zhu HJ; Li JY; Tian LM; Lv DM Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1126-1133. PubMed ID: 32096168 [TBL] [Abstract][Full Text] [Related]
15. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2. Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. Yu Z; Deng P; Chen Y; Liu S; Chen J; Yang Z; Chen J; Fan X; Wang P; Cai Z; Wang Y; Hu P; Lin D; Xiao R; Zou Y; Huang Y; Yu Q; Lan P; Tan J; Wu X Adv Sci (Weinh); 2021 Dec; 8(23):e2100759. PubMed ID: 34881526 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154 [TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746 [TBL] [Abstract][Full Text] [Related]
19. Positive expression of basic transcription factor 3 predicts poor survival of colorectal cancer patients: possible mechanisms involved. Liu Q; Wu J; Lu T; Fang Z; Huang Z; Lu S; Dai C; Li M Cell Death Dis; 2019 Jul; 10(7):509. PubMed ID: 31263147 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Zhang J; He P; Xi Y; Geng M; Chen Y; Ding J Oncotarget; 2015 Feb; 6(5):2917-27. PubMed ID: 25595900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]